PEAK

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Retrieved on: 
金曜日, 6月 14, 2024
PEAK, Congress, Division, Patient, EHA, Bone marrow, Stromal cell, Clinical trial, Disease, Safety, Brain, Physician, Duke University, APEX, Associate, Cogent, Dizziness, MD, Poster, Deficit spending, GIST, Part, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., June 14, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis (NonAdvSM). The data are being presented today in a poster presentation at the 2024 European Hematology Association (EHA) Congress taking place in Madrid, Spain.

Key Points: 
  • and BOULDER, Colo., June 14, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis (NonAdvSM).
  • The data are being presented today in a poster presentation at the 2024 European Hematology Association (EHA) Congress taking place in Madrid, Spain.
  • “We are excited to share additional analyses from SUMMIT Part 1 which highlight substantial symptomatic reductions as well as improvement in objective measures of disease,” said Andrew Robbins, Chief Executive Officer at Cogent Biosciences.
  • I believe bezuclastinib shows promise in treating nonadvanced systemic mastocytosis where significant unmet needs remain.”
    SUMMIT is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 clinical trial of bezuclastinib in patients with NonAdvSM.

PEAK:AIO Solves Power, Density and Ransomware Challenges with New PEAK:ARCHIVE Massive 1.4PB per 2U All-Flash AI Storage, Archive and Compliance Solution

Retrieved on: 
火曜日, 6月 4, 2024
PEAK, Automation, Bias, Organization, Ethics, QLC, Software, Documentation, AI, HDD, Health, 2U, Computer data storage

As AI projects transition from development to production, the need for robust data management solutions becomes critical.

Key Points: 
  • As AI projects transition from development to production, the need for robust data management solutions becomes critical.
  • This market is increasingly facing archive and compliance demands that require a careful balance of scale, cost, and power efficiency.
  • PEAK:ARCHIVE addresses these challenges by delivering a fully automated, out-of-the-box immutable large-scale flash solution that ensures comprehensive backup, archiving, and compliance while protecting against ransomware.
  • Ransomware Protection: Immutable data storage safeguards against tampering and ensures data integrity even in the event of a ransomware attack.

Magnit Named Leader in Everest Group’s 2024 VMS PEAK Matrix® Assessment for the Fourth Consecutive Year

Retrieved on: 
木曜日, 6月 13, 2024
Data Management, Professional Services, Technology, Software, Human Resources, PEAK, Organization, Work, IWM, MSP, Contingent work, Vision, Capability, VMS

Magnit™ , an Integrated Workforce Management (IWM) platform provider, announced that it was named a Leader in Everest Group’s Vendor Management System (VMS) PEAK Matrix® Assessment 2024 for the fourth consecutive year.

Key Points: 
  • Magnit™ , an Integrated Workforce Management (IWM) platform provider, announced that it was named a Leader in Everest Group’s Vendor Management System (VMS) PEAK Matrix® Assessment 2024 for the fourth consecutive year.
  • According to Everest Group, Magnit also achieved the highest positioning for Vision & Capability for the fourth straight year, underscoring the company’s tech-forward strategy and exceptional value proposition compared to other solutions available on the market.
  • “Earning Leader designation for the fourth consecutive year in Everest Group’s VMS PEAK Matrix® showcases our continued dedication to innovation, influencing the evolution of work and creating meaningful business outcomes for our clients,” said Vidhya Srinivasan, Chief Marketing and Product Officer of Magnit.
  • Moreover, its MSP capabilities, analytics prowess, and vision to integrate proprietary tools into its VMS have collectively contributed to its position as a Leader in Everest Group's global VMS PEAK Matrix® Assessment 2024."

UiPath Named a Leader in Everest Group’s Process Mining Products PEAK Matrix® Assessment 2024

Retrieved on: 
木曜日, 6月 13, 2024
Software, Technology, Artificial Intelligence, Data Management, SAP, PEAK, Automation, Salesforce, Process mining, Autopilot, Organization, Mining, Documentation, Hand, ServiceNow, Aspirants, AI, Assessment, Investment, Discovery, Machine learning, ROI, Noise, Risk management

UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced that for the fifth consecutive year it has been named a Leader in the Everest Group Process Mining Products PEAK Matrix® Assessment 2024 .

Key Points: 
  • UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced that for the fifth consecutive year it has been named a Leader in the Everest Group Process Mining Products PEAK Matrix® Assessment 2024 .
  • UiPath Process Mining transforms transactional data from backend systems such as SAP, Salesforce, ServiceNow, and Oracle into visual interactive dashboards.
  • Process Mining reveals the current state of the process, enabling organizations to identify automation and improvement potential in end-to-end business processes.
  • Everest Group’s Process Mining Products PEAK Matrix® Assessment is an annual industry assessment providing analysis and insights on process mining vendors and products to assist enterprises in their selection processes.

Celonis Named a Leader for Fifth Consecutive Year and Star Performer in 2024 Everest Group PEAK Matrix® for Process Mining

Retrieved on: 
水曜日, 6月 12, 2024
Other Manufacturing, Environment, Technology, Professional Services, Software, Manufacturing, Mining, Minerals, Data Analytics, Natural Resources, Artificial Intelligence, PEAK, Intelligence, Ecosystem, Process mining, Pharma, CRM, Growth, Yoy, CPG, LATAM, OCPM, Intelligent automation, AI, Running, Star, Health, Process management, BFSI, ERP

Celonis , the global leader in Process Mining and Process Intelligence , is recognized as a Leader in the Everest Group Process Mining PEAK Matrix® Assessment 2024 for the fifth year in a row and a Star Performer for 2024.

Key Points: 
  • Celonis , the global leader in Process Mining and Process Intelligence , is recognized as a Leader in the Everest Group Process Mining PEAK Matrix® Assessment 2024 for the fifth year in a row and a Star Performer for 2024.
  • As stated in the report, key highlights include:
    Celonis continues to dominate the market in terms of process mining software revenue.
  • Celonis has the largest customer base of process mining clients.
  • Celonis continues to hold the highest share of the process mining market across Continental Europe, North America, the UK, APAC, and LATAM.

Korn Ferry Recognized for Seventh Consecutive Year as a Leader in Everest Group’s Recruitment Process Outsourcing (RPO) Services PEAK Matrix® Assessment 2024

Retrieved on: 
金曜日, 5月 31, 2024
Professional Services, Data Analytics, Technology, Human Resources, Software, Consulting, Outsourcing Business, KFNR, Workforce, Investment, Ferry, PEAK, RPO, Korn Ferry, Recruitment, Aspirants

Korn Ferry (NYSE: KFY) announced today that it has been named as a Leader in Everest Group’s Recruitment Process Outsourcing (RPO) Services PEAK Matrix® Assessment 2024, making it the seventh consecutive year that Korn Ferry has been recognized as a Leader in RPO.

Key Points: 
  • Korn Ferry (NYSE: KFY) announced today that it has been named as a Leader in Everest Group’s Recruitment Process Outsourcing (RPO) Services PEAK Matrix® Assessment 2024, making it the seventh consecutive year that Korn Ferry has been recognized as a Leader in RPO.
  • The report highlights several accomplishments in Korn Ferry’s RPO offering that led to its ranking as a Leader among more than 30 providers, citing the breadth of Korn Ferry’s global delivery footprint to enable the execution of regional and global deals effectively.
  • “Its recent integration of Korn Ferry Nimble Recruit platform, advanced analytics and market intelligence solutions, and its proven expertise in consulting and advisory have contributed to Korn Ferry being positioned as a Leader on Everest Group's Recruitment Process Outsourcing (RPO) Services PEAK Matrix® Assessment 2024 - Global.”
    “We are thrilled that Korn Ferry has been recognized for the seventh consecutive year as a top leader,” said Jeanne MacDonald, President of Korn Ferry’s Global RPO Solutions.
  • The assessment also considers third-party RPO deals as well as approximately 6400 multi-process RPO deals.

UiPath Reports First Quarter Fiscal 2025 Financial Results

Retrieved on: 
水曜日, 5月 29, 2024
Robotics, Apps, Applications, Technology, Software, Electronic Commerce, Artificial Intelligence, Partnership, Developer, Discovery, Ecosystem, Public sector, Automation, Process, FedRAMP, Magic, Publication, PEAK, IDP, Test suite, Risk assessment, Microsoft, Second, Process mining, Research, ARR, GAAP, Mining, ROI, Insurance, Organization, Magic Quadrant, Test automation, AI, Growth, Medical device

UiPath, Inc. (NYSE: PATH), a leading enterprise automation and AI software company, today announced financial results for its first quarter fiscal 2025 ended April 30, 2024.

Key Points: 
  • UiPath, Inc. (NYSE: PATH), a leading enterprise automation and AI software company, today announced financial results for its first quarter fiscal 2025 ended April 30, 2024.
  • We expect the variability of the above charges to have a significant, and potentially unpredictable, impact on our future GAAP financial results.
  • The report assessed UiPath Process Mining, UiPath Task Mining, and UiPath Communications Mining.
  • UiPath will host a conference call today, Wednesday, May 29, 2024, at 5:00 p.m. Eastern Time, to discuss the company's first quarter fiscal 2025 financial results and its guidance for the second quarter and full year fiscal 2025.

ABBYY Recognized as a Leader in Everest Group’s Intelligent Document Processing Products PEAK Matrix® Assessment 2024 for Sixth Consecutive Year

Retrieved on: 
水曜日, 5月 29, 2024
Professional Services, Data Management, Business, Data Analytics, Technology, Software, Artificial Intelligence, Vantage, Partnership, OCR, Automation, Matrix, PEAK, AI, IDP, LLM, Document processing, Classification, Multimedia, Sales

ABBYY has been recognized for the sixth consecutive year as a Leader in Everest Group’s Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2024.

Key Points: 
  • ABBYY has been recognized for the sixth consecutive year as a Leader in Everest Group’s Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240529572319/en/
    Everest Group identified ABBYY as a Leader in its Intelligent Document Processing (IDP) Products PEAK Matrix Assessment® 2024, recognizing ABBYY Vantage for its vision and capabilities as the industry’s only low-code/no-code IDP solution that integrates easily into any intelligent automation platform.
  • (Graphic: Business Wire)
    “ABBYY has reinforced its position as a Leader in Everest Group’s Intelligent Document Processing (IDP) PEAK Matrix® Assessment 2024.
  • To enhance its low-code/no-code IDP platform, Vantage, ABBYY has invested in generative AI enhancements for software learning and training, sentiment recognition, and document summarization.

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Sunitinib, Patient, Progression-free survival, Dana–Farber Cancer Institute, SARC, Clinical trial, Safety, PEAK, Conference, Cogent, Poster, Sarcoma, Harvard Medical School, ASCO, Stromal cell, Associate, Society, APEX, GIST, KIT, Annual general meeting, Pharmaceutical industry

The data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1.

Key Points: 
  • The data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1.
  • “Coupled with the impressive clinical activity demonstrated by the combination, the addition of bezuclastinib to sunitinib continues to be generally well-tolerated with an encouraging safety profile.
  • “Today’s updated lead-in data from the bezuclastinib combination are very promising, and I remain excited about the ongoing PEAK trial.
  • Enrollment continues in the Phase 3 registration-enabling PEAK study, which will include approximately 388 second-line, post imatinib GIST patients.

Cogent Biosciences Reports First Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 7, 2024
AAAAI, American Academy, Brain, Safety, Stromal cell, Mouse, PEAK, Cash, Research, HER2, GIST, ASCO, Patient, Society, AACR, APEX, Edema, G&A, Growth, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2024.
  • Cogent remains on track to complete enrollment in PEAK by the end of 2024 and report top-line results by the end of 2025.
  • G&A expenses include non-cash stock compensation expense of $5.0 million for the first quarter of 2024 as compared to $2.9 million for the first quarter of 2023.
  • Net Loss: Net loss was $58.3 million for the first quarter of 2024 compared to a net loss of $38.6 million for the first quarter of 2023.